Sort   by:  
 Page size 
UnknownSafety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Not available
S-EPMC10150320 | biostudies-literature
UnknownSafety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
Not available
S-EPMC10536880 | biostudies-literature
UnknownPost-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.
Not available
S-EPMC11381616 | biostudies-literature
UnknownEfficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Not available
S-EPMC8693692 | biostudies-literature
UnknownLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Not available
S-EPMC4985288 | biostudies-literature
UnknownSARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.
Not available
S-EPMC11117088 | biostudies-literature
UnknownRisk of COVID-19 after natural infection or vaccination.
Not available
S-EPMC10518569 | biostudies-literature
UnknownInitial Invasive or Conservative Strategy for Stable Coronary Disease.
Not available
S-EPMC7263833 | biostudies-literature
UnknownClinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.
Not available
S-EPMC10346130 | biostudies-literature
UnknownDevelopment of a Definition of Postacute Sequelae of SARS-CoV-2 Infection.
Not available
S-EPMC10214179 | biostudies-literature
Sort   by:  
 Page size